In an era of genomic classifiers, MRI-targeted biopsy, and precision oncology, one might ask: why revisit the natural history of untreated prostate cancer? The answer lies in a persistent tension at the heart of prostate cancer management—the fear of undertreatment for aggressive disease on one hand, and the well-documented harms of overtreatment for indolent disease on the other. Despite decades of data, this tension continues to drive unnecessary radical therapy for men whose tumors would never have harmed them.
This review grew out of a recognized gap: while landmark individual studies (Johansson, Albertsen, SPCG-4, ProtecT) are widely cited, a comprehensive synthesis that spans all staging systems, grading classifications, PSA strata, and age groups—with follow-up extending to 20–30 years—had not been assembled in a single resource. We set out to fill that gap, drawing on 10 major longitudinal cohorts and registries encompassing over 43,000 patients.
The Central Finding: Grade Is Destiny
The single most important takeaway from this synthesis is deceptively simple: tumor grade is the dominant prognostic factor in untreated prostate cancer, outweighing clinical stage and PSA at diagnosis. This is not a new observation—but the consistency and magnitude of the grade effect across disparate cohorts, eras, and continents is striking.
Grade Group 1 (Gleason 6) disease showed metastatic progression rates below 5% over 15–20 years and prostate cancer-specific mortality under 5% at two decades. These are the patients for whom active surveillance was designed, and this review provides robust quantitative backing for that approach. Conversely, Grade Groups 4–5 (Gleason 8–10) were uniformly lethal in conservatively managed cohorts: median time to metastasis was 3–5 years for Gleason 8 and just 1–3 years for Gleason 9–10, underscoring the urgency of early intervention for these men.
The intermediate grades deserve particular attention. The distinction between Gleason 3+4 and 4+3—both classified as "Grade Group 2–3" and both often lumped together as "intermediate risk"—carries meaningful clinical weight. Our synthesis found roughly 2–3 fold differences in 15-year progression rates (35% vs. 55%) and hazard ratios for cancer-specific death of 2.1–3.2 between these two patterns. Clinicians and patients should not treat these as equivalent.
The 15-Year Inflection Point
One of the more nuanced findings—and one that warrants greater emphasis in clinical counseling—is the consistent acceleration of disease progression after approximately 15 years of follow-up. This was most clearly documented in the Swedish Örebro cohort, where annual prostate cancer mortality nearly tripled beyond the 15-year mark (from ~15 to ~44 per 1,000 person-years, p = 0.01), but the pattern was echoed across multiple independent cohorts.
The practical implication is that active surveillance for low-grade disease is not a strategy of indefinite deferral. Patients with long life expectancy—particularly men diagnosed under 60—should understand that the favorable 10–15 year outlook for Gleason 6 disease does not mean lifelong immunity. This inflection point argues for continued surveillance rigor over the long term and should inform how we counsel younger men at diagnosis.
Competing Mortality: Age Changes Everything
The competing mortality analysis in this review offers a valuable corrective to grade-centric thinking. For men over 75—especially those with significant comorbidities—non-cancer mortality dominated the 10-year risk picture regardless of tumor grade. Men over 75 with at least three comorbid conditions and low-grade tumors faced approximately a 14-fold higher risk of dying from causes other than prostate cancer.
This has direct implications for shared decision-making. The decision to pursue active treatment is not simply about tumor biology; it must be contextualized within the patient's overall health trajectory. Our quantitative compilation of age-stratified, competing-risk data can serve as a practical reference in these conversations—offering patients and clinicians a more individualized framework than aggregate statistics alone.
What This Review Does Not Capture—And What Comes Next
We are candid about the limitations of this synthesis. The included studies are primarily European and North American, with predominantly White patient populations. Prostate cancer biology and competing mortality risks differ across ethnic groups, and extrapolation should be done with care. The historical cohorts that contribute most of the long-term data were assembled before contemporary staging, imaging, and pathologic standards—introducing heterogeneity in how "progression" was defined and measured.
What this review cannot do is integrate molecular and genomic risk stratification—tools that have materially changed how we think about individual patients in the PSA era. Tissue-based classifiers (Decipher, Oncotype DX GPS, Prolaris) and liquid biopsy platforms now offer prognostic resolution beyond Gleason grade alone. The natural history data compiled here provide a population-level scaffold; genomic tools are poised to individualize that scaffold for each patient.
The most important future direction is extended follow-up of modern active surveillance cohorts with standardized monitoring protocols. As the Toronto, Johns Hopkins, and multi-institutional CANARY cohorts accumulate 15–20 year outcomes, we will be able to test whether the late progression acceleration seen in historical series persists in carefully selected, PSA-era patients. That answer will define the next generation of surveillance protocols.
A Word on AI-Assisted Manuscript Preparation
Note: This manuscript used AI language tools to assist with language editing and readability. All scientific content, interpretations, and conclusions were generated, reviewed, and endorsed by the author team. We believe transparent disclosure of AI assistance—rather than its prohibition—reflects the reality of contemporary academic writing and supports the integrity of the scientific record.
Written by: Alexis E. Te, MD, and Steven A. Kaplan, MD
- Icahn School of Medicine at Mount Sinai, New York, NY